Immunostimulatory Effects of Silica Nanoparticles in Human Monocytes by �뼇���젙 & 理쒖씤�솉
IMMUNE NETWORK Vol. 13, No. 3: 94-101, June, 2013
ORIGINAL ARTICLE
http://dx.doi.org/10.4110/in.2013.13.3.94
pISSN 1598-2629    eISSN 2092-6685
94
Received on May 9, 2013. Revised on May 22, 2013. Accepted on May 30, 2013.
CC This is an open access article distributed under the terms of the Creative Commons Attribution Non-Commercial 
License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribu-
tion, and reproduction in any medium, provided the original work is properly cited.
*Corresponding Author. In-Hong Choi, Department of Microbiology, Yonsei University College of Medicine, Seoul, Korea. 
Tel: 82-2-2228-1821; Fax: 82-2-392-7088; E-mail: inhong@yuhs.ac
Keywords: Silica nanoparticles, Human monocytes, Cytokine, Inflammasome, Mitochondrial membrane
Abbreviations: ROS, reactive oxygen species; PBMC, peripheral blood monocyte; IL, interleukin
Immunostimulatory Effects of Silica Nanoparticles in Human 
Monocytes
Eun-Jeoung Yang and In-Hong Choi*
Department of Microbiology, The Institute for Immunology and Immunological Diseases, Yonsei University College of Medicine, Seoul 
120-752, Korea
Amorphous silica particles, whose applications are increasing 
in many biomedical fields, are known to be less toxic than 
crystalline silica. In this study, the inflammatory effects of 
amorphous silica nanoparticles were investigated using 30-nm 
amorphous silica nanoparticles and human peripheral blood 
mononuclear cells (PBMCs) or purified monocytes. As a re-
sult, production of IL-1β and IL-8 were increased. In addition, 
the mitochondrial reactive oxygen species (ROS) was de-
tected, which may lead to mitochondrial membrane disrup-
tion. Most importantly, inflammasome formation was obser-
ved. Therefore, these results provide immunological infor-
mation about amorphous silica nanoparticles and suggest 
that amorphous silica nanoparticles can evoke innate im-
mune reactions in human monocytes through production of 
IL-1β and IL-8.
[Immune Network 2013;13(3):94-101]
INTRODUCTION
Silica nanoparticles have been used in various fields, such as 
chemical mechanical engineering, drug delivery, cosmetics, 
printer tones, varnishes, and additives for foods (1-5). Recen-
tly, the applications have been widened to biomedical and 
biotechnological areas, including biosensors for simultaneous 
assay of glucose, lactate, L-glutamate, and hypoxanthine lev-
els in rat striatum (6), biomarkers for leukemia cell identi-
fication using optical microscopic imaging (7), cancer therapy 
(1), DNA delivery (2,8), and drug delivery (9). 
As commodities containing silica nanoparticles have been 
increasing, chances of exposure to silica nanoparticles have 
also been increasing. To date, research into toxicity of silica 
particles has focused on 0.5− to 10-μm crystalline silica. 
However, nano-sized (smaller than 100 nm) silica particles, 
which are becoming more popular these days, apparently 
possess unique toxicological properties compared to 0.5− to 
10-μm silica particles (10). Among crystalline and amorphous 
forms of silica (silicon dioxide, SiO2), the commonest forms 
of free crystalline silica include quartz, tridymite, and 
cristobalite. Natural quartz exists in sandstone (67% silica) 
and granite (25∼40% silica). Amorphous silica can be found 
in diatomaceous earth, opal, silica, and glass (11).
Inhalation of small silica crystals causes acute pulmonary 
inflammation. Chronic occupational exposure to silica crystals 
may induce pneumoconiosis silicosis, which results in pro-
gressive lung fibrosis. However, underlying mechanisms for 
pulmonary inflammation and fibrosis have not yet been fully 
identified (12). After inhaled silica crystals are deposited in 
small airways and phagocytized by resident macrophages, 
pulmonary alveolar macrophages secrete IL-1β or TNF 
(tumor necrosis factor)-α to induce inflammation and TGF 
(transforming growth factor)-β to induce fibrosis. During the 
process, apoptotic cell death occurs to remove unhealthy cells 
containing silica particles. Then, silica particles released from 
dying cells are phagocytized by neighboring macrophages, 
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which evokes further inflammation (13). 
Amorphous silica particles are known to be less toxic than 
crystalline silica. However, the applications of amorphous sili-
ca have been increasing, and nano-sized amorphous silica 
particles have become popular in many biomedical fields. 
Therefore, we investigated the inflammatory effects of amor-
phous silica nanoparticles using 30-nm amorphous silica 
nanoparticles and assessed their effects on human peripheral 
blood mononuclear cells (PBMCs) or purified monocytes. 
Cytotoxicity and production of IL-1β and IL-8 were evalu-
ated. The mitochondrial ROS, mitochondrial membrane in-
tegrity, inflammasome formation, and endosomal localization 
of silica nanoparticles were also assessed. 
MATERIALS AND METHODS
Cell culture and cell purification
After internal review board approval and informed consent 
(No: 4-2012-0088), 100-ml blood was obtained from ten 
healthy donors. PBMCs were separated using ficoll/hypaque 
density gradient (density=1.070−1.074) by centrifugation at 
1,600 rpm for 25 min. PBMCs were cultured in RPMI 1640 
containing 10% FBS and streptomycin/penicillin (each 100 
IU/mL) at 37oC in a moisturized 5% CO2 incubator. Although 
endotoxin was not detected in silica nanoparticles used in this 
study, polymyxin B (InvivoGen, San Diego, CA, USA) at a 
concentration of 10 ng/ml was added as an endotoxin neu-
tralizer. To purify monocytes, PBMCs were incubated for 2 
h in RPMI 1640 containing 1% FBS at 37oC in a moisturized 
5% CO2 incubator, and adherent cells were obtained after dis-
carding non-adherent cells. Staining for CD14, a monocyte 
marker, was performed to identify the monocyte population. 
Cytotoxicity assay
Cell was assessed using a colorimetric cell counting kit-8 
(CCK-8) (Dojindo laboratories, Kyoto, Japan). CCK-8 is based 
on a colorimetric assay utilizing a highly water soluble tetrazo-
lium salt, WST-8 [2-(2-methyxy-4-nitrophenyl)-3-(4-nitrophe-
nyl)-5-(2,4-disulfophenyl)-2H-tetrazolium, monosodium salt]. 
Wells were treated with 200μl of silica nanoparticle solutions 
diluted in cell culture medium. After 6 h, 15μl of CCK-8 re-
agent was added to each well and then incubated at 37oC 
for 2 h. After centrifugation, 100μl of the supernatant was 
transferred to 96-well microtiter plates, and optical densities 
(OD) were measured at 450 nm with a spectrophotometer 
(Molecular Devices, Sunnyvale, CA, USA) to avoid optical in-
terference caused by silica nanoparticles. LPS (E.coli 026:B6; 
Sigma-Aldrich, St Louis, MO, USA) was treated at 25 ng/ml 
for 1 h before exposure of PBMCs to nanoparticles.
Enzyme-linked immunosorbent assay (ELISA)
ELISA was performed to assess IL-1β and IL-8 in the culture 
supernatant. PBMCs were plated in 24-well plates at 2×105 
cells per well in 200μl of RPMI 1640 containing 10% FBS. 
Silica nanoparticles in cell culture media were added to each 
well, making the final volume of 400μl per well. After cul-
ture times were recorded, cell culture supernatants were col-
lected and stored at −80oC. ELISA was performed with a hu-
man IL-1β and IL-8 assay kits (BD Biosciences, San Jose, CA, 
USA) which use biotinylated anti-IL-1β and anti-IL-8, de-
tection antibodies, and streptavidin-horse radish peroxidase. 
OD values were read at 450 nm. 
Staining with MitoSOX and JC-1
Monocytes were treated with silica nanoparticles (125 and 250
μg/ml for 30-nm silica particles) for 40 min for MitoSOX 
staining (for 15 min). After treatment with silica nanoparticles, 
blood monocytes were stained with fluorescent dyes 
(MitoSOX) diluted in Hank’s balanced salt solution for 15∼30 
min at 37oC in the dark. Then, 2.5μM MitoSOX (Invitrogen, 
San Diego, CA, USA) was applied to detect mitochondrial 
superoxide. After exposure to silica nanoparticles, staining 
with 2μM JC-1 (Invitrogen) was performed to determine mi-
tochondrial depolarization. Flow cytometric analysis was per-
formed using a FACScan (Becton Dickinson, Franklin Lakes, 
NJ, USA), and the results were analyzed using WinMDI 
software. 
TEM analysis 
Monocytes were treated with 125μ/ml of silica nanoparticles 
for 15 min and fixed with Karnovsky solution (2% gluta-
raldehyde, 2% paraformaldehyde, 0.5% CaCl2) for 6 h. After 
washing with PBS for 2 h, cells were treated with 1% OsO4 
in 0.1M PBS for 2 h. Dehydration of each sample was per-
formed gradually with 50%, 60%, 70%, 80%, 90%, 95% and 
100% alcohol for 10 min, followed by a final addition of pro-
pylene oxide for 10 min. Samples were then treated with a 
mixture of EPON (EPON 812, MNA, DDSA, DMP30) and pro-
pylene oxide (1：1) for 18 h and heated in an embedding 
oven at 35oC for 6 h, 45oC for 12 h, and 60oC for 24 h. The 
cell block was trimmed and sectioned at 0.25μm using an 
ultramicrotome (Leica Ultracut UCT, Leica Microsystems 
Immunostimulatory Effects of Silica Nanoparticles in Human Monocytes
Eun-Jeoung Yang and In-Hong Choi
96 IMMUNE NETWORK Vol. 13, No. 3: 94-101, June, 2013
Figure 1. Cytotoxicity and produc-
tion of cytokines in PBMCs. (a) 
PBMCs were treated with 30-nm 
amorphous silica nanoparticles for 6
h and cytotoxicity was determined 
by CCK-8 assay. (b, c) PBMCs were
treated with silica nanoparticles for
6 h and supernatant levels of IL-1β
(b) and IL-8 (c) were assessed by 
ELISA. LPS (25 ng/ml) was pre- 
treated for 3 h before nanoparticle 
exposure. Data represent means±
S.D. of three independent experi-
ments. One-way ANOVA analysis 
shows significance (p＜0.0001) (b, c)
and student’s t-test between certain
pairs (b, c) was used for statistical 
analysis.
GmbH, Wetzlar, Germany). These ultra-thin sections were 
stained with 1% toluidine blue and put on a copper grid. The 
samples were then stained with both uranyl acetate (6%) and 
lead citrate, and analyzed using a TEM (JEM-1011, JEOL, 
Tokyo, Japan).
Statistical analysis
Independent Student’s t test and one-way analysis of variance 
(ANOVA) were used to compare the differences between the 
control and study groups. A p-value of ＜0.05 was consid-
ered significant.
RESULTS
Cytotoxicity and cytokine production by PBMCs after 
exposure to 30 nm amorphous silica nanoparticles 
The cytotoxicity of 30-nm silica nanoparticles in PBMCs has 
increased dose-dependently (Fig. 1a) starting at a concen-
tration of 31.3μ/ml. Similar results were obtained after pre-
treatment with a low concentration (25 ng/ml) of LPS for 3 h (Fig. 
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Figure 2. Production of mitochon-
dria ROS in blood monocytes. 
Monocytes were treated with silica 
nanoparticles or silver nanoparti-
cles for 40 min. Cells were stained
with 2.5μM MitoSOX (for mito-
chondrial superoxide) for 15 min 
and analyzed by flow cytometry. 
MI, mean intensity. Data shown 
here are representative results from
three independent experiments.
1a). The LD50 values of silica nanoparticles were 41.8μg/ml with-
out LPS and 41.4μg/ml with LPS. Therefore, the pretreatment 
with LPS at a low concentration did not influence cytotoxicity fol-
lowing exposure to silica nanoparticles. 
After exposure to silica nanoparticles, the levels of IL-1β 
and IL-8 produced by PBMCs increased dose-dependently. 
The IL-1β levels were 0.4, 1.3, and 1.7 ng/ml after treatment 
with silica nanoparticle at concentrations of 31.3, 125, and 
250μg/ml, respectively. When LPS was pretreated, the IL-1β 
levels were higher (6.6, 11.6, and 7.9 ng/ml after treatment with 
silica nanoparticles at concentrations of 31.3, 125, 250μg/ml, 
respectively) than those treated with silica nanoparticles alone 
(Fig. 1b). The IL-8 levels were 4.9, 10.7, and 2.4 ng/ml after 
treatment with silica nanoparticles at concentrations of 31.3, 
125, and 250μg/ml, respectively. When LPS was pretreated, 
the IL-8 levels were higher (13.1, 19.4, and 6.3 ng/ml after 
treatment with silica nanoparticles at concentrations of 31.3, 
125, and 250μg/ml) than those treated with silica nano-
particles alone (Fig. 1c). After pretreatment with LPS, pro-
duction of IL-8 started to decrease at a silica nanoparticle con-
centration of 250μg/ml. After pretreatment with LPS, pro-
duction of IL-1β or IL-8 started to decrease at a silica nano-
particle concentration of 250μg/ml. These results suggest 
that PBMCs primed with LPS become vulnerable to the fol-
lowing stimuli. Therefore, PBMCs respond more sensitively 
at lower concentrations of the following stimuli, but they be-
come exhausted and do not respond to higher concentrations 
of the following stimuli.
Superoxide generation and deterioration of mitoc-
hondrial membranes in monocytes 
After purification of monocytes from PBMCs, generation of 
superoxide was detected by MitoSOX and expressed as MI. 
As shown in Fig. 2, the MIs were 497 at a silica nanoparticle 
concentration of 125μg/ml and 555 at a silica nanoparticle 
concentration of 250μg/ml. When compared to the results 
of 5-nm silver nanoparticles, which were used as a positive 
control, silica nanoparticles induced significantly lower levels 
of superoxide. Silica nanoparticles operated at higher concen-
trations than silver nanoparticles, which was due to different 
characteristics of individual nanoparticles. The LD50 of 5-nm 
silver nanoparticles is 0.48μg/ml (14), whereas that of 30 nm 
silica particles is 41.8μg/ml. In our study, 100-nm silver 
nanoparticles were used as a negative control because they 
do not trigger monocytes at 0.6∼0.9μg/ml (14).
Since MitoSOX detects superoxide at mitochondrial mem-
brane, which may induce deterioration of mitochondrial 
membrane, we assessed mitochondrial membrane potential. 
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Figure 3. Assessment of mitochon-
drial membrane integrity. Mono-
cytes were treated with 125μg/ml
of 30 nm silica nanoparticles for 1
h, 1.5 h, and 2 h. After exposure 
for the indicated time, JC-1 (2μM)
staining was performed to evalu-
ate disturbance of mitochondrial 
membranes. Cells stained as red 
(intact mitochondria) were deter-
mined by flow cytometry. Data 
shown here are representative re-
sults from three independent ex-
periments. MI, mean intensity.
JC-1 staining revealed the disturbance of mitochondrial mem-
brane after exposure to 30-nm silica nanoparticles. The per-
centage of mitochondrial staining decreased by 51.5% at 1 h, 
by 50.4% at 1.5 h, and by 50.0 % at 2 h (Fig. 3). The control 
level was 60.5%, which was detected without exposure to sili-
ca nanoparticles. 
Inflammasome formation in monocytes 
To determine the inflammasome formation by silica nanopar-
ticles, monocytes were stained with anti-NLRP3 and anti-cas-
pase-1 antibodies after exposure to nanoparticles. As a result, oli-
gomerization of NLRP3 and caspase-1 was detected 15 min after 
exposure to silica nanoparticles at a concentration of 125μg/ml 
(Fig. 4). Oligomerization of NLRP3 and caspase-1 was not 
found in control cells which were not exposed to silica 
nanoparticles.
Endocytosis of silica nanoparticles in monocytes
Next, the presence of silica nanoparticles and intracellular 
changes in monocytes were assessed via TEM. Within 30 min 
after treatment with silica nanoparticles at a concentration of 
125μg/ml, double membrane structures suggestive of auto-
phagosomes were found as indicated with white arrows (Fig. 
5a). Silica nanoparticles also were detected in endosomes 
(Fig. 5b).
DISCUSSION
The aim of this study was to provide information on in-
flammatory effects of amorphous silica nanoparticles. As re-
ported previously, crystalline silica nanoparticles induce NLRP3 
inflammasome to secrete IL-1β, which is mediated by particle 
uptake, rupture of lysosomal membrane, and release of cathe-
psin B (15,16). The subsequent secretion of IL-1β is known 
to be responsible for silicosis (17). In contrast, the results 
from amorphous silica nanoparticles vary depending on par-
ticle size and cell types (18-20). Therefore, in our study using 
human PBMCs or purified monocytes, the effects of amor-
phous silica nanoparticles were assessed. 
Maturation of IL-1β is tightly regulated by NLRP3, 1 of the 
4 inflammasome types (21). Thus, even if pro-IL-1β protein 
is present inside a cell, it cannot be released until NLRP3 in-
flammasomes are formed. Upon proper assembly of NLRP3 
inflammasomes, caspase-1 is activated and cleaves the pro- 
form of IL-1β to generate mature IL-1β. Mature IL-1β is then 
released from cells to perform their respective immunological 
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Figure 4. Inflammasome formation
of caspase-1 and NLRP3 in mono-
cytes. To analyze oligomerization 
of NLRP3 and caspase-1, mono-
cytes were treated with silica na-
noparticles (125μg/ml) for 15 min.
Oligomerization of NLRP3 and ca-
spase-1 was assessed by confocal 
microscopy after staining with an-
ti-NLRP3 and anti-caspase-1 an-
tibodies. White arrows indicate 
oligomerization of each molecule, 
which are not observed in con-
trols.
Figure 5. TEM images of monocytes after exposure to silica nano-
particles. Monocytes were treated with silica nanoparticles (125μg/ml)
for 30 min. After 30 nm silica nanoparticle exposure, (a) double mem-
brane structures (white arrows) suggesting autophagy-like structures 
and (b) presence of silica nanoparticles were observed inside en-
dosome.
functions. Therefore, factors triggering inflammasome for-
mation are also critical for producing functional IL-1β.
We assessed the responses of human PBMCs after treat-
ment with silica nanoparticles. As expected, 30-nm amor-
phous silica nanoparticles induced IL-1β production in hu-
man PBMCs. We further speculated that silica nanoparticles 
may increase IL-1β production when pretreated with a low 
concentration of LPS. These findings suggest that the im-
munological relevance of silica nanoparticles should be con-
sidered with regard to their synergistic effects on minimally 
activated immune responses.
To simulate an in vivo environment we purified monocytes 
from PBMCs and assessed inflammasome formation. Previous 
immunological studies with nanoparticles mainly focused on 
macrophage cell lines, but not primary monocytes. It has 
been reported that macrophages and monocytes have differ-
ent pathways to produce inflammasomes. While macro-
phages require 2 signals to release mature IL-1b, the first sig-
nal to produce pro-IL-1β protein and the second signal to 
activate NLRP3, monocytes constitutively express active ca-
sapse-1 and require only 1 signal for IL-1β release (22). 
To activate caspase-1, inflammasome formation is a prere-
quisite. During inflammasome formation, oligomerization of 
NLRP3 occurs simultaneously with oligomerization of cas-
pase-1. Confocal findings of monocytes treated with 30-nm 
silica nanoparticles suggest that oligomerization of NLRP3 or 
caspase-1 occurs rapidly as early as 15 min after exposure 
to nanoparticles. We investigated mechanisms underlying in-
flammasome formation following exposure to silica nano-
particles. ROS has been suggested to be a causative factor 
in the induction of the inflammasome complex. There have 
been many reports on the sources of ROS, such as perox-
isomes, nitric oxide synthases, oxidoreductin 1, and cytosolic 
enzymes including cyclooxygenase, in the endoplasmic retic-
Immunostimulatory Effects of Silica Nanoparticles in Human Monocytes
Eun-Jeoung Yang and In-Hong Choi
100 IMMUNE NETWORK Vol. 13, No. 3: 94-101, June, 2013
ulum (23,24). However, the majority of ROS are produced 
as a by-product of the mitochondrial electron transport chain 
in cells undergoing aerobic metabolism (25). Although TiO2 
(26), silica (27) and silver nanoparticles (14) produce ROS, 
there have been few reports that have identified the types 
of ROS produced. In our study, ROS was evaluated by assess-
ing the production of mitochondria superoxide. Recently, su-
peroxide in the mitochondrial membrane was reported to trig-
ger inflammasome formation (14,28) in specific structures 
called mitochondria-associated ER membranes (29). Our re-
sults showed that 30-nm silica nanoparticles more increased 
production of mitochondrial superoxide than 100-nm silver 
nanopaticles and that collapse of the mitochondrial membrane 
was observed in blood monocytes 1 h, 1.5 h, and 2 h after 
treatment with 30-nm silica nanoparticles.
Collectively, inflammasome formation in monocytes was 
observed after exposure to amorphous silica nanoparticles. 
However, rupture of the endolysosomal membrane which 
was shown in crystalline silica was not detected in our study. 
These findings suggest that induction of superoxide and sub-
sequent deterioration of the mitochondrial membrane may be 
one of the major factors in the induction of inflammasome 
formation in amorphous silica nanoparticles. 
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